Home > Patient Guide > Team

Team: Staff Profile

Robert L. Fine, MD

Address:	Black Building 650 West 168th Street 20-05 New York, NY 10032
Phone:	212.305.1168
Fax:	212.305.7348

< Back to Staff List

Positions and Appointments

2006 – Present	Director, Medical Oncology, The Pancreas Center Columbia University College of Physicians & Surgeons/NewYork-Presbyterian Hospital, New York, NY
2000 – Present	Herbert Irving Associate Professor of Medicine Division of Medical Oncology Columbia University College of Physicians & Surgeons New York, NY
1998 – Present	Member, Columbia University Ph.D. Thesis Committee in Biomedical Engineering
1999 – Present	Member, Columbia University School of Public Health Ph.D. Thesis Committee
1997 – Present	Director, Clinical Pharmacology Core Lab Facility Irving Comprehensive Cancer Center

The Pancreas Center Specialty

Medical Oncology — Program Director

Education and Training

1982 – 1988	Fellowship Oncology National Cancer Institute, Bethesda, MD
1979 – 1982	Residence Internal Medicine Stanford University Hospital, Stanford, CA
1975 – 1979	Medical Degree University of Chicago Pritzker School of Medicine, Chicago, IL
1971 – 1975	B.S., Biochemistry and Philosophy Stockton College, Pomona, NJ

Board Certifications

1980	Diplomat, National Board of Medical Examiners (No. 221562)
1983	Diplomat, American Board of Internal Medicine Examiners (No. 089279)
1985	Diplomat, American Board of Internal Medicine, Medical Oncology (Subspecialty No. 089279)

Professional Experience

1997 – 2000	Herbert Irving Assistant Professor of Medicine Division of Medical Oncology Columbia University College of Physicians and Surgeons New York, NY
1995 – 2006	Director, Experimental Therapeutics Program NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY
1995 – 1999	Assistant Professor of Medicine Columbia University College of Physicians and Surgeons NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY
1990 – 1995	Assistant Professor of Pharmacology Duke University School of Medicine, Durham, NC
1989 – 1995	Director of Hematology/Oncology Clinic, Durham VA Hospital
1988 – 1995	Assistant Professor of Medicine Division of Hematology/Oncology Duke University and Durham VA Medical Centers, Durham, N.C.
1986 – 1988	Medical Investigator Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, MD
1985 – 1988	Attending for Medicine Branch National Cancer Institute, NIH, Bethesda, MD
1982– 1988	U.S. Public Health Service. Lt. Commander, Grade 0-4

Professional Honors

2006 – 2008	Chemotherapy Foundation Grant in Pancreatic Cancer
2006 – 2008	R.C. Hayes Foundation Grant in Pancreatic Cancer
2006 – 2007	"Best Doctors in U.S." by Castle Connelly
2006 – 2007	"Best Oncologists" in NY, NJ, PA, CT by New York Magazine
2005	Pancreatic Cancer Research Award by Advanced Research Foundation
2005	One of Top 3 leaders in pancreatic cancer in U.S. voted by Oncology Physicians-Biomedical Insight Survey
2005 – 2008	Cordaro Foundation Award for Pancreatic Cancer Research
2004 – 2007	S.G. Kaplansky Award for Pancreatic Cancer Research
2004 – 2007	Manelski Foundation for Pancreatic Cancer Research Grant
2003 – 2006	Herbert Pardes Clinical Scholar Award
2001 – 2002	Herbert Irving Translational Cancer Award
2000 – 2001	Avon Foundation Scholar Award
1999 – 2000	Glaxo Wellcome Translational Scholar Award
1996 – 1999	Herbert Irving Scholar Award: Columbia University
1993	General Medicine Attending Teaching Award: Duke University
1986	American Society of Clinical Oncology Abstract Awards
1986	American Society of Clinical Oncology Travel Award
1979	Research Honors: University of Chicago Pritzker Medical School
1978 – 1979	Public Health Service/NIH National Cancer Institute Senior COSTEP Scholarship
1979	Summa Cum Laude, University of Chicago Pritzker Medical School
1977	American Cancer Society Student Grant
1976 – 1978	Eva Leventhal Medical Scholarship
1975 – 1976	Women's Auxiliary to Atlantic County Medical Society Scholarship
1975 – 1978	Atlantic County Medical Society Scholarship
1975	Stockton Scholar Award and Stockton Advanced Study Award
1974	American Cancer Society Student Scholarship

Recent Committee Memberships and Professional Societies

American Association for Advancement Science
American Association Cancer Research
Board member, AACR Awards Selection Committee
American Society Clinical Oncology
Children's Oncology Group
Southwest Oncology Group (SWOG)
Board member, SWOG Experimental Therapeutics Committee
Veterinary Oncology Association

Selected Publications

Fine, R.L., Fogelman, D.R., Sherman, W. and Chabot, J. Alternating Cell Cycle Block with Docetaxel — Gemcitabine/Capecitabine (T-GX) Overcomes Clinical Resistance to GTX Chemotherapy in Pancreatic Cancer Patients. In preparation

Li, Y., Yao, P.M., Mao, Y. and Fine, R.L. The Synergistic Induction of Apoptosis by Alternating Docetaxel-Gemcitabine/Capecitabine (T-GX) in Pancreatic Cancer Cells is Mediated by Selective Activation of p38 and c-JUN MAPK Pathways. In preparation.

Yao, P.M., Mao, Y., Dinnen, R.D., Li, Y. and Fine, R.L. The Biochemical Mechanism of Synergy of GTX Chemotherapy for Pancreatic Cancer is Mediated by Selective Inhibition of MEK1/2-ERK1/2 Phosphorylation. In preparation.

Mao, Y, Li, Y, Dinnen, R.D. and Fine, R.L. The Synergistic Mechanism of Action for p53 Peptide and Paclitaxel Induces Fas/Fas Ligand in Pancreatic Cancer Cells In Vitro. In preparation.

Chabot, J.A., Tsai, W-Y., Fine, R.L., Chen, C., Kumar, C.K., Gabay, M., Antman, K.A., and Grann, V.R. Pancreatic Proteolytic Enzyme Therapy vs. Gemcitabine-based Chemotherapy for the Treatment of Pancreatic Cancer (PANCAM). J. Clin. Oncol. — submitted.

Mao, Y., Brandt-Rauf, P., Nichols, G., and Fine, R.L. A Modified Bidirectionally Controlled p14ARF Promoter Linked to Biscistronic p14 and t-BID Construct Induces Selective Intrinsic and Extrinsic Pathways of Apoptosis in Cancer Cells with Mutant ras and Mutant p53. — submitted.

Mao, Y., Rosal, R.V., Li, Y., Senatus, P., Bruce, J., Nichols, G., Brandt-Rauf, P., Fine, R.L. C-terminalp53 Palindromic Tetrapeptide Restores Full Apoptotic Potential to Mutant p53 Cancer Cells In Vitro and In Vivo. Nature Medicine — submitted.

Dinnen, R., Rosal, R.V., Cassai, N., Nichols, G., Slavkovic, V.N., Brandt Rauf, P and Fine, R.L. Switching from Apoptosis to Aponecrosis in Pancreatic Cancer Cells Through Redox Cycling of Disulfiram, Driven by Arsenic Trioxide and Ascorbic Acid-generated Reactive Oxygen Species. Cell Death and Differentiation — submitted.

Vinarsky, V., Fine, R.L., Assaad, A., Qian, Y., Chabot, J.A., Su, G. H., Frucht, H. FAMMM Syndrome Variant With Head and Neck Squamous Cell Carcinoma. J. Natl. Cancer Inst. — submitted.

Dinnen, R., Rosal, R.V., Cassai, N., Nichols, G., Slavkovic, V.N., Brandt Rauf, P and Fine, R.L. Re-directing Apoptosis to Aponecrosis in Pancreatic Cancer Cells Through Redox Cycling of Disulfiram, Driven by Arsenic Trioxide and Ascorbic Acid-generated ROS. Molecular Cancer Therapeutics — accepted.

Schonleben, F., Qiu, W., Li, X., Ho, D.J., Ciau, N.T., Chabot, J.A., Allendorf, J.D., Fine, R.L., Remotti, H.E., Su, G.H. Mutational Analyses of Multiple Oncogenic Pathways in Intraductal Papillary Mucinous Neoplasms(IPMN/IPMC) of the Pancreas. Europ. J. Cancer – accepted and Pancreas – in press.

Fine, R.L., Fogelman, D., Schreibman, S.M., Strauss, J., Sherman, W., Guba, S., Andrade, R., and Chabot, J. The Gemcitabine, Docetaxel, and Capecitabine (GTX) regimen for metastatic pancreatic cancer: A retrospective review. Cancer Chemotherapy and Pharmacology 6(1), January 2008.

Allendorf, J.D., Lauerman, M., Bill, A., DiGiorgi, M., Goetz, N., Remotti, H., Vakiani, E., Schrope, B., Sherman, W., Hall., M., Fine, R.L., and Chabot, J.A. Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy and Survival. J. Gastrointest Surg. Epub 2007 Sep 5.

Dinnen, R.D., Drew, L., Mao, Y., Petrylak, D., Cassai, N., Szmulewicz, J., Brandt-Rauf, P., ,Fine, R.L., Activation of Targeted Necrosis by a p53 Peptide: A Novel Death Pathway which Circumvents Apoptotic Resistance. J. Biol. Chem. 2007 Sep 14;282(37):26675-86. Epub 2007 Jul 18.

Lebedeva, I.V., Washington, I., Sarkar, D., Clark, J.A., Fine, R.L., Dent, P., Curiel, D.T., Turro, N.J., and Fisher, P.B. Strategy for Inhibiting Resistance to a Single Anti-cancer Agent in Human Prostate and Pancreatic Carcinomas. Proc. Natl. Acad. Sci. — 104: 3484-3489, 2007.

Fine, R.L., Shah, S.S., Yu, I., Moulton, T.A., Fogelman, D.R., Richardson, M.,Burris, H.A., Samuels, B.L., Assanasen, C., Gorroochurn, P., Goldman, F.D.,Dubovsky, D., Walterhouse, D and Halligan, G. Androgen and c-Kit Receptors in Desmoplastic Small Round Cell Tumors (DSRCT) Resistant to Chemotherapy: Novel targets for therapy. Cancer Chemoth. Pharmacol. Online 8/06; published – 59:429 – 437, 2007.

Michl, J, Scharf, B, Schmidt, A, Huynh, C, Hannan, R, von Gizycki, H, Friedman, F, Brandt Rauf, P, Fine, RL, Pincus, MR. PNC, a p53-derived Peptide that is Cytotoxic to Cancer Cells and Blocks Pancreatic Cancer Cell Growth In Vivo. Int. J. Cancer – 119: 1577 – 1585, 2006.

Kaufman, H.L., Harandi, A., Watson, M.C, Varter, E.L., DeRaffele, G., Shahid, M. and Fine, R.L. Panniculitis After Vaccination Against CEA and MUC 1 in a Patient with Pancreatic Cancer. Lancet Oncology 6: 62-63, 2005.

Khorana, A. and Fine, R.L. Pancreatic Cancer and Thromboembolic Disease. Lancet Oncology 5: 655-661, 2004.

Fogelman, D., Chen, J., Chabot, J., Allendorf, J., Shrope, B. Ennis, R., Schreibman, S. and Fine, R.L. The Evolution of Adjuvant and Neoadjuvant Chemotherapy and Radiation for Advanced Pancreatic Cancer: From 5-FU to GTX. Surgical Oncology Clinics of North America 13: 711-735, 2004.

Frucht, H., Stevens, P.D., Fogelman, D.R., Verna, E.C., Chen, J., Chabot, J.A. and Fine, R.L. Advances in the genetic screening, work-up, and treatment of pancreatic cancer. Current Treatment Options in Gastroenterology, 7: 343-354, 2004.

Reviews, Chapters, and Editorials

Fogelman, D. and Fine, R.L. "Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine/Docetaxel/Capecitabine". Case Studies in Oncology. Vol. 5, No. 1, April, 2003.

Balmaceda, C. and Fine, R.L. "Gliomas". In Merritt's Textbook of Neurology. Rowland (ed.) Lippincott-Williams and Wilkins, Phila., PA. 10th edition, 2000, pgs 318-333.

Fine, R.L. Rubin, J.S., "Emerging Applications for Somatostatin Analogues in Oncology". 1998. Monograph in a series.

Fine, R.L., Sachs, C.W., Safa, A. Rao, U.S., Scarsborough, G., Burchette, J., Albers, M.A., Trump, D.L. Tamoxifen inhibition of MDR: Laboratory to clinical studies. In The Mechanisms and New Approaches to Drug Resistance in Cancer Cells. Miyazaki, T., Takaku F., Sakurada, E. (Eds.) Elsevier Press, Amsterdam, Netherlands, 1993, pp. 323-332.

Fine, R.L., Peritoneoscopy (Laparoscopy): Applications to the Diagnosis and Treatment of Intra-Abdominal Malignancies. In Cancer Medicine, 3rd Edition. Holland, J.F., Frei E., Bast, R.C., Kuffe, D., Morton, D., Weichselbaum, R. (Eds.). Lea and Febiger, Phila., P.A. Chapter XI-3, 1993, pp. 513-522.

APPOINTMENT CENTER

What to expect from an appointment with a specialist:

Appointment Request Form
Directions to the Center